1-trityl-1H-1,2,4-triazole-3-carboxylic acid ethyl ester | 280570-75-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: 1-trityl-1H-1,2,4-triazole-3-carboxylic acid ethyl ester
• 英文别名: 1-Trityl-1,2,4-triazole-3-carboxylic acid ethyl ester；ethyl 1-trityl-1,2,4-triazole-3-carboxylate
• CAS: 280570-75-4
• 化学式: C₂₄H₂₁N₃O₂
• 分子量: 383.45
• InChiKey: PPCIEUKDUGSCOC-UHFFFAOYSA-N

物化性质

• 沸点：
  562.9±60.0 °C(Predicted)
• 密度：
  1.15±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  29
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  57
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-[1-[(4-氟苯基)甲基]吡咯-2-基]乙酮 、 1-trityl-1H-1,2,4-triazole-3-carboxylic acid ethyl ester 以 四氢呋喃 为溶剂， 反应 3.5h， 以54%的产率得到1-(1-(4-fluorobenzyl)-1H-pyrrol-2-yl)-3-hydroxy-3-(1-trityl-1H-1,2,4-triazol-3-yl)prop-2-en-1-one
  参考文献：
  名称：

  Structure–Activity Relationship of Pyrrolyl Diketo Acid Derivatives as Dual Inhibitors of HIV-1 Integrase and Reverse Transcriptase Ribonuclease H Domain

  摘要：

  The development of HIV-1 dual inhibitors is a highly innovative approach aimed at reducing drug toxic side effects as well as therapeutic costs. HIV-1 integrase (IN) and reverse transcriptase-associated ribonuclease H (RNase H) are both selective targets for HIV-1 chemotherapy, and the identification of dual IN/RNase H inhibitors is an attractive strategy for new drug development. We newly synthesized pyrrolyl derivatives that exhibited good potency against IN and a moderate inhibition of the RNase H function of RT, confirming the possibility of developing dual HIV-1 IN/RNase H inhibitors and obtaining new information for the further development of more effective dual HIV-1 inhibitors.

  DOI：

  10.1021/jm501799k
• 作为产物：
  描述：

  1H-1,2,4-三氮唑-3-羧酸乙酯 、 三苯基氯甲烷 在 N,N-二异丙基乙胺 作用下， 以 DMF (N,N-dimethyl-formamide) 为溶剂， 反应 2.0h， 以66%的产率得到1-trityl-1H-1,2,4-triazole-3-carboxylic acid ethyl ester
  参考文献：
  名称：

  EP1186599

  摘要：

  公开号：

文献信息

• Aromatic heterocycle compounds having HIV integrase inhibiting activities
  申请人：Shionogi & Co., Ltd.

  公开号：US06620841B1

  公开（公告）日：2003-09-16

  A compound of the formula (I): wherein X is hydroxy, protected hydroxy or optionally substituted amino; Y is —COORA wherein RA is hydrogen or ester residue, —CONRBRC wherein RB and RC each is independently hydrogen or amide residue, optionally substituted aryl or optionally substituted heteroaryl; and A1 is optionally substituted heteroaryl; provided that a compound wherein Y and/or A1 is optionally substituted indol-3-yl is excluded, a tautomer, a prodrug, a pharmaceutically acceptable salt or a hydrate thereof has an inhibitory activity against an integrase.

  公式（I）的化合物：其中X是羟基，保护羟基或可选择取代的氨基；Y是—COORA，其中RA是氢或酯基，—CONRBRC，其中RB和RC分别独立地是氢或酰胺基，可选择取代的芳基或可选择取代的杂环芳基；而A1是可选择取代的杂环芳基；前提是化合物中Y和/或A1为可选择取代的吲哚-3-基团的化合物被排除在外，其互变体、前药、药学上可接受的盐或水合物对整合酶具有抑制活性。
• Medicinal compositions containing propenone derivatives
  申请人：——

  公开号：US20030171406A1

  公开（公告）日：2003-09-11

  A combination of an integrate inhibitor with an anti-retrovirus active substance and medical compositions containing the same as the active ingredients are found.

  一种将整合抑制剂与抗逆转录病毒活性物质组合使用的医药组合物被发现，该组合物以其作为活性成分。
• Indole derivatives having an antiviral activity
  申请人：——

  公开号：US20030181499A1

  公开（公告）日：2003-09-25

  A compound of the formula: 1 wherein R 1 is hydrogen, lower alkyl, or optionally substituted arylsulfonyl, or the like, R 2 is hydrogen, lower alkyl, or optionally substituted aralkyl, or the like, R 3 , R 4 , R 5 , and R 6 each is independently hydrogen, halogen, trihalogenated lower alkyl, or the like, X is hydroxy or optionally substituted amino, Y is COOR (E is hydrogen or an ester residue), optionally substituted aryl, or optionally substituted heteroaryl, has integrase inhibition activity, and is useful as an anti-HIV drug.

  该化合物的公式为1，其中R1为氢、较低的烷基、或可选取代的芳基磺酰基等；R2为氢、较低的烷基、或可选取代的芳基烷基等；R3、R4、R5和R6分别独立地为氢、卤素、三卤代较低的烷基等；X为羟基或可选取代的氨基；Y为COOR（E为氢或酯基残基）、可选取代的芳基或可选取代的杂环基。该化合物具有整合酶抑制活性，可用作抗HIV药物。
• Heteroaromatic derivatives having an inhibitory activity against HIV integrase
  申请人：——

  公开号：US20040002485A1

  公开（公告）日：2004-01-01

  A compound of the formula (I): 1 wherein X is hydroxy, protected hydroxy or optionally substituted amino; Y is —COOR A wherein R A is hydrogen or ester residue, —CONR B R C wherein R B and R C each is independently hydrogen or amide residue, optionally substituted aryl or optionally substituted heteroaryl; and A 1 is optionally substituted heteroaryl; provided that a compound wherein Y and/or A 1 is optionally substituted indol-3-yl is excluded, a tautomer, a prodrug, a pharmaceutically acceptable salt or a hydrate thereof has an inhibitory activity against an integrase.

  式(I)的化合物：其中X为羟基，保护羟基或可选取代的氨基；Y为—COORA，其中RA为氢或酯基残基，—CONRBRC，其中RB和RC各自独立地为氢或酰胺基残基，可选取代的芳基或可选取代的杂芳基；且A1为可选取代的杂芳基；但其中Y和/或A1为可选取代的吲哚-3-基的化合物被排除，其互变异构体、前药、药物可接受的盐或水合物具有对整合酶的抑制活性。
• Inhibitor for enzyme having two divalent metal ions as active centers
  申请人：——

  公开号：US20040039060A1

  公开（公告）日：2004-02-26

  A pharmaceutical composition for use as an inhibitor of an enzyme having two divalent metal ions as an active center was found. It is possible to inhibit the activity of an enzyme by a compound capable of chelating both of the two divalent metal ions.

  发现了一种用作酶抑制剂的药物组合物，该酶具有两个二价金属离子作为活性中心。能够通过一种化合物来螯合这两个二价金属离子，从而抑制酶活性。